Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 313

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)

Miller, Robert G, Mitchell, J D, Lyon, Mary, Moore, Dan H·2007·Cochrane Database of Systematic Reviews

Abstract

BACKGROUND: Riluzole has been approved for treatment of patients with amyotrophic lateral sclerosis in most countries. Questions persist about its clinical utility because of high cost and modest efficacy. OBJECTIVES: To examine the efficacy of riluzole in prolonging survival, and in delaying the use of surrogates (tracheostomy and mechanical ventilation) to sustain survival. SEARCH STRATEGY: We searched the Cochrane Neuromuscular Disease Group Register for randomized trials in December 2004 and made enquiries of authors of trials, Aventis (manufacturer of riluzole) and other experts in the field. We searched MEDLINE (January 1966 to August 25 2006) and EMBASE (January 1980 to September 30th 2006). SELECTION CRITERIA: Types of studies: randomized trials. TYPES OF PARTICIPANTS: adults with a diagnosis of amyotrophic lateral sclerosis. Types of interventions: treatment with riluzole or placebo. Types of outcome measures: Primary: pooled hazard ratio of tracheostomy-free survival over all time points with riluzole 100 mg. Secondary: per cent mortality with riluzole 50, 100 and 200 mg; neurologic function, muscle strength and adverse events. DATA COLLECTION AND ANALYSIS: We identified four eligible randomized trials. MAIN RESULTS: The four trials examining tracheostomy-free survival included a total of 974 riluzole treated patients and 503 placebo treated patients. The methodological quality was acceptable and three trials were easily comparable, although one trial included older patients in more advanced stages of amyotrophic lateral sclerosis and one had multiple primary endpoints. Riluzole 100 mg per day provided a benefit for the homogeneous group of patients in the first two trials (P value = 0.042, hazard ratio 0.80, 95% confidence interval 0.64 to 0.99) and there was no evidence of heterogeneity (P value = 0.33). When the third trial (which included older and more seriously affected patients) was added, there was evidence of heterogeneity (P value < 0.0001) and the random effects model, which takes this into account, resulted in the overall treatment effect estimate falling just short of significance (P value = 0.056, hazard ratio 0.84, 95% confidence interval 0.70 to 1.01). This represented a 9% gain in the probability of surviving one year (57% in the placebo and 66% in the riluzole group). There was a small beneficial effect on both bulbar and limb function, but not on muscle strength. A threefold increase in serum alanine transferase was more frequent in riluzole treated patients than controls (weighted mean difference 2.62, 95% confidence interval 1.59 to 4.31). AUTHORS' CONCLUSIONS: Riluzole 100 mg daily is reasonably safe and probably prolongs median survival by about two to three months in patients with amyotrophic lateral sclerosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd001447.pub2

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Research works printed but not linked: 15

  1. Yanagisawa, 1997, Efficacy and safety of riluzole in patients with amyotrophic lateral sclerosis: double-blind placebo-controlled study in Japan, Igakuno Ayumi, 182, 851
  2. Arriada-Mendicoa, 1999, Open label study of riluzole for the treatment of amyotrophic lateral sclerosis, Revista Ecuatoriana de Neurologia, 8, 33
  3. Couratier, 2000, Interest of a computerized ALS database in the diagnosis and follow-up of patients with ALS, Revue Neurologique, 156, 357
  4. Palma, 2000, An open study of riluzole versus riluzole plus gabapentin in amyotrophic lateral sclerosis, Journal of the Peripheral Nervous System, 5, 46, 10.1046/j.1529-8027.2000.00513-45.x · doi:10.1046/j.1529-8027.2000.00513-45.x
  5. Pongratz, 1999, Open-label trial of riluzole 50 mg b.i.d. in treatment of amyotrophic lateral sclerosis (ALS), Aktuelle Neurologie, 26, 225, 10.1055/s-2007-1017633 · doi:10.1055/s-2007-1017633
  6. Brooks, 2001, Survival in non-riluzole treated amyotrophic lateral sclerosis (ALS) - Motor neuron disease (MND) patients with disease onset before and since 1996 is identical: a clinic-based epidemiological study, ALS and other motor neuron diseases, 2, 60
  7. Hugon, 1996, ALS therapy: targets for the future, Neurology, 47, 251, 10.1212/WNL.47.6_Suppl_4.251S · doi:10.1212/wnl.47.6_suppl_4.251s
  8. Lacomblez, 1989, A double-blind, placebo-controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis, Neurology, 39, 1635, 10.1212/WNL.39.12.1635 · doi:10.1212/wnl.39.12.1635
  9. Meininger, 1997, The Riluzole Early Access Programme: descriptive analysis of 844 patients in France. ALS/Riluzole Study Group III, Neurology, 244, S22, 10.1007/BF03160577 · doi:10.1007/bf03160577
  10. Meininger, 2004, Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials, Amyotrophic lateral sclerosis and other motor neuron disorders, 5, 107, 10.1080/14660820410019602 · DOI
  11. Miller, 1996, Clinical trials of riluzole in patients with amyotrophic lateral sclerosis, Neurology, 47, S86, 10.1212/WNL.47.4_Suppl_2.86S · doi:10.1212/wnl.47.4_suppl_2.86s
  12. 1997, Practice advisory on the treatment of amyotrophic lateral sclerosis with riluzole, Neurology, 49, 657, 10.1212/WNL.49.3.657 · doi:10.1212/wnl.49.3.657
  13. Rowland, 1994, Riluzole for the treatment of amyotrophic lateral sclerosis - too soon to tell?, New England Journal of Medicine, 330, 636, 10.1056/NEJM199403033300911 · doi:10.1056/nejm199403033300911
  14. Traynor, 2001, Riluzole and prognosis in ALS: Findings of the Irish ALS register over a five year study period (1999-2000), Amyotrophic lateral sclerosis and other motor neuron disorders, 2, 43
  15. Turner, 2001, The Kings' Database 1999-2000: an analysis of the effect on survival of interventions in amyotrophic lateral sclerosis, Amyotrophic lateral sclerosis and other motor neuron disorders, 2, 43

Cited by

See all 313

Metadata

Authors
Miller, R. G., Mitchell, J. D., Lyon, M., & Moore, D. H.
Venue
Cochrane Database of Systematic Reviews
Published
2007-01-24
Issue
1
Pages
CD001447-CD001447
ISSN
1361-6137 (ISSN-L)
OpenAlex
W4229619638
Cited by
313
References
21
Type
reference entry
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). https://app.cochat.ai/papers/10.1002/14651858.cd001447.pub2
The paper
Miller, R. G., Mitchell, J. D., Lyon, M., & Moore, D. H. (2007). Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd001447.pub2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.